TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00002634
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002634
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01563029
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT04316702
Drug: Cymbalta / Lyrica - Drug treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: one of the two medications currently licensed for the treatment of FMS in Israel, i.e. Cymbalta and Lyrica. Two medications currently licensed for the treatment of FM in Israel, i.e. Cymbalta and Lyrica. Treatment with Lyrica will start at a dose of 75 mg twice a day, at morning and at bedtime, while treatment with Cymbalta will start at a dose of 30 mg a day (in the morning).
Study: NCT03814421
Drug: intermittent (40mg as a bolus injection daily for 72hours)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current guidelines recommend an intravenous bolus dose of a proton pump inhibitor(PPI) followed by continuous PPI infusion after endoscopic therapy in patients with high-risk bleeding peptic ulcers. However, recent many studies suggests intermittent low dose PPI infusion might have equal efficacy at preventing peptic ulcer hemorrhage recurrence. So, the present investigator assumed that intermittent administration of proton pump inhibitor will not be different from administration of continuous proton pump inhibitor for the prevention of rebleeding in patients with peptic ulcer bleeding. Also, intermittent proton pump inhibitor administration in patients with high risk of rebleeding (Rockall score 6 points or more) will not be different from prevention of rebleeding compared with continuous proton pump inhibitor administration.
Study: NCT00713830
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self administered by subcutaneous injections once daily within the hour preceding breakfast.
Study: NCT00713830
Drug: Sulfonylurea
Normalized name: Sulfonylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfonylurea to be continued at maximum effective dose according to local labeling up to end of treatment.
Study: NCT03199924
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular injection of 75mg / 3ml of Diclofenac solution
Study: NCT03992261
Drug: Halobetasol Topical Foam
Normalized name: halobetasol Topical Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foam
Study: NCT03229174
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sugar pill)
Study: NCT03642704
Drug: Reinforced preventive ARV therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: If the mother is HIV-1 or HIV 1/2 infected:~* zidovudine / laminvudine (60/30 mg), ¼ cp morning and evening orally for 12 weeks.~* nevirapine: 15mg/OD if weight ≥ 2500g / 10mg/OD if weight = 2000-2499g / 2mg/kg/OD if weight \< 2000g for 12 weeks in case of HIV-1 infection. After 6 weeks, nevirapine will increase at 20mg/OD~If the mother is HIV-2 infected:~- zidovudine / laminvudine (60/30 mg), ¼ cp morning and evening orally for 12 weeks.
Study: NCT01724619
Drug: [F-18] fluorinated dihydrotestosterone (FDHT)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01146886
Drug: Placebo to BI 135585
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1 - oral doses given to approximately 9 parallel groups of 8 subjects (6 on active and 2 on on placebo) on Day 1
Study: NCT00983255
Drug: TR-701 FA for injection, 200 mg/vial
Approvals — FDA: no, EMA: no, PMDA: no
Description: TR-701 FA for injection will be given as a single infusion at doses of 50 mg, 100 mg, 200 mg, and 400 mg in SAD/Part A (Pilot and Cohorts 1 to 3). TR-701 FA for injection will be given as once daily infusions at doses of 200 mg and 400 mg for 7 days in MAD/Part B (Cohorts 4 \& 5). TR-701 FA for injection will be given once as a 200 mg IV infusion in BA/Part C (Cohort 6). TR-701 FA 200 mg will be given daily for 3 days in Venous Tolerability/Part D
Study: NCT00866229
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 mg per day for 12 weeks
Study: NCT00866229
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg per day
Study: NCT03279393
Drug: fluorodeoxyglucose (FDG)-PET/MRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Innovative PET combined with magnetic resonance imaging (PET/MRI) to simultaneously study the hematopoietic system, the artery wall, and the brain's fear system, which comprises the amygdala and anterior cingulate cortex (ACC)
Study: NCT00983255
Drug: TR-701 FA tablets
Normalized name: Folic Acid Tablets
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TR-701 FA will be given once orally as a 200 mg tablet in Part C.
Study: NCT01261780
Drug: Sham device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham therapy daily x 45 minutes for 10 treatments (given over course of 2 weeks)
Study: NCT03123120
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 weeks treatment
Study: NCT00663039
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose (plus a booster dose) drug probe study using intranasal placebo
Study: NCT01402193
Drug: Pre-radiotherapy commencement of Arimidex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arimidex:1mg P.O. daily will be prescribed for 8 weeks in post-mastectomy patients and 9 weeks in BCT patients within the study period. Arimidex starts 3 weeks before adjuvant radiotherapy and throughout the course of radiotherapy.Total duration of adjuvant hormonotherapy is prescribed by the investigators at the completion of study, 5 years in principle.
Study: NCT01402193
Drug: Post radiotherapy commencement of Arimidex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arimidex：1mg P.O. daily will be prescribed at 2 weeks after the end of radiotherapy.Total duration of adjuvant hormonotherapy is prescribed by the investigators at the completion of study, 5 years in principle.
Study: NCT00108108
Drug: HCD122
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04525885
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet administered orally BID
Study: NCT00448110
Drug: Intravenous Diclofenac (DIC075V)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Diclofenac (DIC075V): 1 of 2 dosage levels
Study: NCT00448110
Drug: Intravenous Ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Ketorolac
Study: NCT00448110
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT03450330
Drug: AZD4205
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose of AZD4205, followed by daily dose of AZD4205 and Osimertinib 80 mg. Starting dose of AZD4205 at 75 mg, administered once daily. If tolerated, subsequent cohorts will test increasing doses of AZD4205, and in combination with Osimertinib 80 mg.
Study: NCT00002680
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03005210
Drug: Magicbuvir Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
Study: NCT04271488
Drug: Tasurgratinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tasurgratinib oral tablet.
Study: NCT04271488
Drug: Tasurgratinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tasurgratinib oral capsule.
Study: NCT00713765
Drug: AZD3480
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 total doses of 40 mg, on days 1-18
Study: NCT02890966
Drug: SHR4640
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day1\~Day7:oral administration
Study: NCT02890966
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day1\~Day7:oral administration
Study: NCT01642615
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexlansoprazole placebo-matching capsules
Study: NCT04431674
Drug: Definity Suspension for Injection
Normalized name: Definity Suspension for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRI-guided ultrasound-stimulated microbubble-treatment
Study: NCT04323956
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04323956
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03497598
Drug: Lactose
Normalized name: Lactose
DrugBank: Lactose (DB04465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The powder is dispensed in 2g neutral sticks and ready to be dissolved in 100ml of water for daily oral ingestion.
Study: NCT00184951
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00667173
Drug: IDP-115
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application for 12 weeks
Study: NCT00667173
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application for 12 weeks
Study: NCT03400956
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally, coated tablet, once daily
Study: NCT01409343
Drug: TrasGEX™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received TrasGEX intravenously every 3 weeks until disease progression in doses of 12-720 mg in a three-plus-three dose escalation design, including an expansion cohort at the highest dose.
Study: NCT02206178
Drug: N-acetylcysteine combination with acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02206178
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03311828
Drug: Imaging Agent
Normalized name: NON-IMAGING AGENTS RADIOPHARMACEUTICALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given Copper 64Cu-DOTA-daratumumab IV
Study: NCT02358356
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral capecitabine 750mg/m2 b.i.d.
Study: NCT02819908
Drug: Imprimis Less Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pred-Moxi-Ketorolac and Pred-Ketorolac topical instillation qd postoperatively
Study: NCT01143740
Drug: RO5045337
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally day 1-10 each 28-day cycle, 3 cycles
Study: NCT03259620
Drug: CLS006
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide Topical Gel
Study: NCT03259620
Drug: CLS006 Vehicle
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle Topical Gel
Study: NCT02285062
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00345969
Drug: Transdermal Testosterone gel (1%)
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone replacement therapy with Androgel(TM). Daily application of gel at 5 mg, 7.5 gm, or 10 gm for six months. Target serum total testosterone level between 500-900 ng/dl.
Study: NCT02285062
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02285062
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02365623
Drug: Background Regimen (BR)
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive anti-bacterial tuberculosis drugs (pyrazinamide \[PZA\], ethambutol \[EB, EMB\], streptomycin \[SM\], kanamycin \[KM, KAN\], enviomycin \[EVM\], ethionamide \[TH\], cycloserine \[CS\], para-aminosalicylic acid \[PAS\], amikacin \[AMK\], levofloxacin \[LVFX\] and other fluoroquinolone. Other drugs are used less commonly, such as amoxicillin-clavulanate, linezolid and clofazimine based on Investigator's decision twice a week from Day 1 up to 78 weeks after conversion or 102 weeks after day 1 (what happens first).
Study: NCT01845623
Drug: QAB149 75 mg Concept 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: QAB149 delivered via the concept 1 device.
Study: NCT01845623
Drug: QAB149 75 mg Epic Test Fixture
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: QAB149 delivered via the EPIC test fixture
Study: NCT04008927
Drug: HCV treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct-Acting Antiviral drugs will be prescribed for 8 or 12 weeks according to liver assessment.
Study: NCT04097379
Drug: LRX712
Approvals — FDA: no, EMA: no, PMDA: no
Description: LRX712 intra-articular injections
Study: NCT04097379
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intra-articular injections
Study: NCT03914326
Drug: Placebo (semaglutide)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets to be taken with water at the same time every morning in a fasting state
Study: NCT02896621
Drug: Chlorthalidone plus amiloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: A capsule with chlorthalidone plus amiloride was taken once daily in the morning for eight weeks.
Study: NCT01090895
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of placebo(saline solution) 10 minutes before percutaneous coronary intervention.
Study: NCT02125734
Drug: QVA149
Approvals — FDA: no, EMA: no, PMDA: no
Description: QVA149 capsules 110/50 µg for inhalation via Concep-1-inhaler device, taken once a day
Study: NCT01190735
Drug: Caffeine alkaloid
Normalized name: belladonna alkaloids / caffeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: The following intervention will be provided for six consecutive weeks:~Week 1 (100 mg BID), Week 2 (200 mg BID), Week 3 (300 mg BID), Week 4 (400 mg BID), Week 5 and 6(500 mg BID). At the conclusion of the study, patients will decrease their dose by 100 mg BID every other day, until caffeine is stopped. This gradual reduction will be to prevent withdrawal symptoms. If a patient experiences a dose-limiting event, they will be terminated from the study, and will withdraw from the medication in the same manner. If dose-limiting events occur between visits, patients will be encouraged to decrease the caffeine dose back to the previously-tolerated dose until in-person assessment can be performed.
Study: NCT02903095
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00710762
Drug: BIBF1120
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00710762
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02631473
Drug: +/- 200mg NANO-Lopinavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID
Study: NCT02631473
Drug: +/- 200mg ritonavir NORVIR
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID
Study: NCT02631473
Drug: 400mg Sustiva
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04397770
Drug: SHR1210
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
Study: NCT03131427
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care according to the updated national and/or international guidelines
Study: NCT00002501
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03279289
Drug: 5Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m2 intravenous bolus
Study: NCT02299661
Drug: DS-1093a
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-1093a, single oral doses up to 50 mg
Study: NCT01964391
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin will be administered in combination with trastuzumab and cyclophosphamide in the adjuvant setting as per local Product Information and the investigator's discretion.
Study: NCT01964391
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be administered in combination with trastuzumab and doxorubicin in the adjuvant setting as per local Product Information and the investigator's discretion.
Study: NCT03104816
Drug: Acetaminophen IV Soln 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03104816
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04643600
Drug: L-Arginine, 500 Mg Oral Capsule
Normalized name: L-Arginine, 500 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: The strength test of the the quadriceps muscle, will be measured in all patients on the Biodex isokinetic device. Quadriceps strength testing will be performed on 2 occasions. On one occasion without medication, except those that the patient may take permanently, and on the other 90 minutes after the patient takes 1 tbl of L - Arginine 500 mg on mouth to an empty stomach ,in order to monitor the possible increase in quadriceps strength.
Study: NCT00334178
Drug: Laxymig ER (drug)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04064359
Drug: OBT076, a CD205-directed antibody-drug conjugate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) infusion of OBT076 every 3 weeks.
Study: NCT01527786
Drug: Desvenlafaxine
Normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg-100mg everyday for 12 weeks over 7 study visits
Study: NCT00204438
Drug: 0.15mg desogestrel /0.03mg ethinyl estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01904773
Drug: AZD5213 and placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: low dose AZD5213 capsules; high dose AZD5213 capsules; placebo capsules
Study: NCT02876250
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: a control group with IV administration of 2.5 mg/kg of placebo prior to first graft reperfusion
Study: NCT03626298
Drug: Nicotinamide, ABA and Zinc PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination of three non-antibiotic active ingredients of nicotinamide, anti-bacterial adhesive agent (ABA) and zinc, or abbreviated as ANAZ to be well-tolerated by patients with acne vulgaris
Study: NCT03985293
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 matching placebo tablets taken twice a day (BID)
Study: NCT03626298
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream. to resemble an active medication or therapy so that it functions as a control; this is to prevent the recipient(s) and/or others from knowing (with their consent) whether a treatment is active or inactive, as expectations about efficacy can influence results.
Study: NCT00791076
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2pmol/kg-1/min-1 placebo infused continuously over 72 hours.
Study: NCT02718599
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive 50 ml normal saline at a rate of 100 ml/h followed by a continuous infusion of 50 ml at a rate equal to wt/10 ml per hour and weaned in the postoperative period over 4 hours.
Study: NCT01873417
Drug: BG00012 (DMF)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00458016
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral administration
Study: NCT01106469
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT02183701
Drug: Losartan + Hydrochlorothiazide
Normalized name: hydrochlorothiazide / losartan
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02183701
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02361476
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection - during surgery
Study: NCT04565327
Drug: Hyperpolarized Carbon C 13 Pyruvate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV prior to imaging
Study: NCT00814333
Drug: Merocel pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 cm pack, inserted within the affected side between the septum and inferior turbinate via bayonet forceps
Study: NCT00830791
Drug: MK-0941 20 mg
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 10-mg tablets of MK-0941 administered as a single oral dose.
Study: NCT00830791
Drug: MK-0941 5 mg
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0941 administered as one single 5-mg tablet.
Study: NCT00010062
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00711165
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 puffs, qd
Study: NCT03010475
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral administration. A total of three single doses.
Study: NCT03010475
Drug: SNAC
Normalized name: Glucerna Snack Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration. A total of five single doses.
Study: NCT04450316
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tab nightly
Study: NCT01396499
Drug: BKM120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose 80 mg tablets by mouth daily for a 28 day cycle.
Study: NCT04950660
Drug: Caffeine Tablet
Normalized name: Caffeine Tablets
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine is approved by the FDA as a stimulant. A stimulant approved by the United States Food and Drug Administration (FDA) for the treatment to increase mental alertness and in combination with painkiller to treat migraine headaches. It is approved in the form of pill or tablet.
Study: NCT04950660
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, empty opaque dark blue blank capsule, taken twice daily. This will be an adjuvant to their standard pain control.
Study: NCT04470726
Drug: AIV001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal/intratumoral
Study: NCT04470726
Drug: AIV001 suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIV001 is administered as a aqueous suspension by an intradermal/intratumoral injection
Study: NCT03427788
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo, once daily in an escalating manner as LSF or tablets
Study: NCT02111798
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be randomly assigned to receive placebo powder in twice-daily capsules at the end of week 2.
Study: NCT03341741
Drug: Tobramycin Powder
Normalized name: tobramycin Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: TOBI®Podhaler 2 x 112 mg daily for 2 x 28 days (on/off);